The neurofilament light chain is not stable in vitro

Annals of Neurology

Volumn 69, Issue 6, 2011, Pages 1065-1066

  Koel Simmelink, Marleen J A ^a   Teunissen, Charlotte E ^a   Behradkia, Payam ^a   Blankenstein, Marinus A ^a   Petzold, Axel ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AXONAL INJURY; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; LETTER; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROFILAMENT; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; HUMANS; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS;

EID: 79959436497     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22438     Document Type: Letter

References (5)

1. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
2. Petzold A,. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183-198. (Pubitemid 40804835)
3. Teunissen CE, Dijkstra C, Polman C,. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41. (Pubitemid 40023234)
4. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-1922.
5. Petzold A, Keir G, Green AJE, et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003; 278: 179-190. (Pubitemid 37281201)